Tango Therapeutics Inc [TNGX] stock is trading at $1.21, down -4.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The TNGX shares have lost -5.47% over the last week, with a monthly amount drifted -34.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tango Therapeutics Inc [NASDAQ: TNGX] stock has seen the most recent analyst activity on July 17, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $19. On February 12, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $18 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $16 on December 08, 2023. H.C. Wainwright upgraded its rating to a Buy but $10 remained the price target by the analyst firm on October 20, 2022. SVB Leerink started tracking with a Outperform rating for this stock on September 20, 2021, and assigned it a price target of $25.
Tango Therapeutics Inc [TNGX] stock has fluctuated between $1.12 and $12.02 over the past year. Currently, Wall Street analysts expect the stock to reach $14.67 within the next 12 months. Tango Therapeutics Inc [NASDAQ: TNGX] shares were valued at $1.21 at the most recent close of the market. An investor can expect a potential return of 1112.4% based on the average TNGX price forecast.
Analyzing the TNGX fundamentals
Tango Therapeutics Inc [NASDAQ:TNGX] reported sales of 42.07M for the trailing twelve months, which represents a drop of -24.19%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -3.46%, Pretax Profit Margin comes in at -3.09%, and Net Profit Margin reading is -3.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.55 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1500 points at the first support level, and at 1.0900 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3000, and for the 2nd resistance point, it is at 1.3900.
Ratios To Look Out For
For context, Tango Therapeutics Inc’s Current Ratio is 6.98. On the other hand, the Quick Ratio is 6.98, and the Cash Ratio is 1.82. Considering the valuation of this stock, the price to sales ratio is 3.11, the price to book ratio is 0.65.
Transactions by insiders
Recent insider trading involved Barry Douglas, General Counsel, that happened on Feb 04 ’25 when 2774.0 shares were sold. General Counsel, Barry Douglas completed a deal on Feb 05 ’25 to sell 2556.0 shares. Meanwhile, Chief Financial Officer Beckman Daniella sold 4284.0 shares on Feb 04 ’25.
